Marsha A Raebel1, Robert Penfold2, Ann W McMahon3, Marsha Reichman4, Susan Shetterly5, Glenn Goodrich5, Susan Andrade6, Christoph U Correll7, Tobias Gerhard8. 1. Kaiser Permanente Colorado Institute for Health Research, Denver, Colorado; marsha.a.raebel@kp.org. 2. Group Health Research Institute, Seattle, Washington; 3. Office of Pediatric Therapeutics, Office of the Commissioner, and. 4. Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland; 5. Kaiser Permanente Colorado Institute for Health Research, Denver, Colorado; 6. Meyers Primary Care Institute, a joint endeavor of Fallon Community Health Plan, Reliant Medical Group, and University of Massachusetts Medical School, Worcester, Massachusetts; 7. The Zucker Hillside Hospital, Psychiatry, Glen Oaks, New York; and. 8. Rutgers University, Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey, and Ernest Mario School of Pharmacy, Piscataway, New Jersey.
Abstract
OBJECTIVES: In 2003, the US Food and Drug Administration issued warnings about hyperglycemia and diabetes with second-generation antipsychotics (SGAs); guidelines have recommended metabolic screening since 2004. However, little is known of contemporary practices of glucose screening among youth initiating SGAs. Our objective was to evaluate baseline glucose assessment among youth in the Mini-Sentinel Distributed Database starting an SGA. METHODS: The cohort included youth ages 2 through 18 newly initiating SGAs January 1, 2006, through December 31, 2011, across 10 sites. Baseline glucose was defined as fasting/random glucose or hemoglobin A1c (GLU) measurement occurring relative to first SGA dispensing. Differences in GLU assessment were evaluated with χ(2) tests and logistic regression. RESULTS: The cohort included 16,304 youth; 60% boys; mean age 12.8 years. Risperidone was most commonly started (43%). Eleven percent (n = 1858) had GLU assessed between 90 days before and 3 days after first dispensing. Assessment varied across SGAs (olanzapine highest), sites (integrated health care systems higher), ages (16-18 highest), years (2007 highest), and gender (female higher; all P < .001). GLU assessment among those starting olanzapine was more likely than among those starting quetiapine (odds ratio [OR]: 1.72 [95% confidence interval (CI): 1.37-2.18]), aripiprazole (OR: 1.49 [95% CI: 1.18-1.87]), or risperidone (OR: 1.61 [95% CI: 1.28-2.03]). CONCLUSIONS: Few children and adolescents starting SGA have baseline glucose assessed. This is concerning because those at high diabetes risk may not be identified. Further, lack of screening impedes determining the contribution of SGAs to hyperglycemia development.
OBJECTIVES: In 2003, the US Food and Drug Administration issued warnings about hyperglycemia and diabetes with second-generation antipsychotics (SGAs); guidelines have recommended metabolic screening since 2004. However, little is known of contemporary practices of glucose screening among youth initiating SGAs. Our objective was to evaluate baseline glucose assessment among youth in the Mini-Sentinel Distributed Database starting an SGA. METHODS: The cohort included youth ages 2 through 18 newly initiating SGAs January 1, 2006, through December 31, 2011, across 10 sites. Baseline glucose was defined as fasting/random glucose or hemoglobin A1c (GLU) measurement occurring relative to first SGA dispensing. Differences in GLU assessment were evaluated with χ(2) tests and logistic regression. RESULTS: The cohort included 16,304 youth; 60% boys; mean age 12.8 years. Risperidone was most commonly started (43%). Eleven percent (n = 1858) had GLU assessed between 90 days before and 3 days after first dispensing. Assessment varied across SGAs (olanzapine highest), sites (integrated health care systems higher), ages (16-18 highest), years (2007 highest), and gender (female higher; all P < .001). GLU assessment among those starting olanzapine was more likely than among those starting quetiapine (odds ratio [OR]: 1.72 [95% confidence interval (CI): 1.37-2.18]), aripiprazole (OR: 1.49 [95% CI: 1.18-1.87]), or risperidone (OR: 1.61 [95% CI: 1.28-2.03]). CONCLUSIONS: Few children and adolescents starting SGA have baseline glucose assessed. This is concerning because those at high diabetes risk may not be identified. Further, lack of screening impedes determining the contribution of SGAs to hyperglycemia development.
Authors: Robert O Cotes; Alex de Nesnera; Michael Kelly; Karen Orsini; Haiyi Xie; Greg McHugo; Stephen Bartels; Mary F Brunette Journal: Community Ment Health J Date: 2015-02-03
Authors: Christoph U Correll; Linmarie Sikich; Gloria Reeves; Jacqueline Johnson; Courtney Keeton; Marina Spanos; Sandeep Kapoor; Kristin Bussell; Leslie Miller; Tara Chandrasekhar; Eva M Sheridan; Sara Pirmohamed; Shauna P Reinblatt; Cheryl Alderman; Abigail Scheer; Irmgard Borner; Terrence C Bethea; Sarah Edwards; Robert M Hamer; Mark A Riddle Journal: World Psychiatry Date: 2020-02 Impact factor: 49.548
Authors: Marsha A Raebel; Susan M Shetterly; Bharati Bhardwaja; Andrew T Sterrett; Emily B Schroeder; Joseph Chorny; Tyson P Hagen; David J Silverman; Rex Astles; Ira M Lubin Journal: Popul Health Manag Date: 2019-05-20 Impact factor: 2.459
Authors: Marsha A Raebel; LeeAnn M Quintana; Emily B Schroeder; Susan M Shetterly; Lisa E Pieper; Paul L Epner; Laura K Bechtel; David H Smith; Andrew T Sterrett; Joseph A Chorny; Ira M Lubin Journal: Arch Pathol Lab Med Date: 2018-12-10 Impact factor: 5.534
Authors: Rosa Gini; Martijn Schuemie; Jeffrey Brown; Patrick Ryan; Edoardo Vacchi; Massimo Coppola; Walter Cazzola; Preciosa Coloma; Roberto Berni; Gayo Diallo; José Luis Oliveira; Paul Avillach; Gianluca Trifirò; Peter Rijnbeek; Mariadonata Bellentani; Johan van Der Lei; Niek Klazinga; Miriam Sturkenboom Journal: EGEMS (Wash DC) Date: 2016-02-08
Authors: Lenneke Minjon; Ivona Brozina; Toine C G Egberts; Eibert R Heerdink; Els van den Ban Journal: Front Psychiatry Date: 2021-02-25 Impact factor: 4.157